Clinical trial transparency improves at (some) biopharmas as J&J, Sanofi lead a pack trailed by Valeant and Allergan
Drug makers appear to be more transparent with their clinical trial data than they used to be, according to a new analysis by a coalition of researchers. But not all pharmas are not equally forthright.
The group, led by not-for-profit Bioethics International, looked at clinical trial registration, results reporting, clinical study report synopsis sharing and journal publication rates for new drugs approved by the FDA in 2014. Specifically, they zeroed in on large pharmaceutical companies, and ranked them by transparency metrics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.